What is Zacks Research’s Estimate for Perrigo Q1 Earnings?

Perrigo Company plc (NYSE:PRGO) – Stock analysts at Zacks Research lowered their Q1 2026 earnings per share estimates for Perrigo in a research note issued to investors on Thursday, March 19th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.57 per share for the quarter, down from their previous forecast of $0.78. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.55 EPS, Q4 2026 earnings at $0.61 EPS, FY2026 earnings at $2.18 EPS, Q1 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.63 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $2.53 EPS.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the company posted $0.93 EPS. Perrigo’s revenue for the quarter was down 2.5% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Several other equities research analysts have also commented on the stock. Argus raised shares of Perrigo to a “hold” rating in a research note on Wednesday, January 14th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Canaccord Genuity Group dropped their price target on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. JPMorgan Chase & Co. cut their price target on Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $19.33.

Perrigo Stock Down 4.2%

Shares of Perrigo stock opened at $9.25 on Monday. Perrigo has a 1 year low of $9.23 and a 1 year high of $28.43. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -0.90, a PEG ratio of 1.09 and a beta of 0.41. The company has a 50-day moving average of $13.29 and a 200 day moving average of $16.01. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.76 and a quick ratio of 1.63.

Institutional Trading of Perrigo

Several large investors have recently modified their holdings of PRGO. EverSource Wealth Advisors LLC lifted its holdings in Perrigo by 116.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares during the period. Geneos Wealth Management Inc. grew its stake in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the period. UMB Bank n.a. increased its position in shares of Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Perrigo in the 4th quarter worth approximately $28,000. Finally, CWM LLC lifted its stake in shares of Perrigo by 230.0% in the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock worth $31,000 after purchasing an additional 1,527 shares during the period. Institutional investors own 95.91% of the company’s stock.

Perrigo Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 12.5%. The ex-dividend date of this dividend is Monday, March 2nd. Perrigo’s dividend payout ratio is presently -11.28%.

Perrigo News Summary

Here are the key news stories impacting Perrigo this week:

• Negative Sentiment: Zacks slashed Q1–Q4 2026 and several 2027 quarterly estimates, lowering FY2026 EPS to $2.18 (from $3.00) and FY2027 to $2.53 (from $3.18) — signaling weaker near‑term profit expectations and prompting a “Hold” stance. MarketBeat: Zacks Lowers Perrigo Estimates
• Negative Sentiment: Zacks specifically cut quarterly EPS forecasts across multiple quarters (e.g., Q1 2026 to $0.57 from $0.78; Q2 2026 to $0.45 from $0.63; Q3/Q4 2026 and several 2027 quarters also reduced), increasing the risk that Perrigo will need to re‑accelerate margins or growth to meet consensus. MarketBeat: Zacks Lowers Quarterly Estimates
• Negative Sentiment: Separate coverage summarizing Zacks’ Q2 estimate and commentary reiterated the weaker consensus outlook for near‑term EPS — reinforcing the market’s negative reaction to the downgraded profitability trajectory. Zacks Research Estimates Perrigo’s Q2 Earnings

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.